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P-TEFb, comprised of CDK9 and a cyclin T subunit, is a global transcriptional elongation factor important
for most RNA polymerase II (pol II) transcription. P-TEFb facilitates transcription elongation in part by
phosphorylating Ser2 of the heptapeptide repeat of the carboxy-terminal domain (CTD) of the largest subunit
of pol II. Previous studies have shown that P-TEFb is subjected to negative regulation by forming an inactive
complex with 7SK small RNA and HEXIM1. In an effort to investigate the molecular mechanism by which
corepressor N-CoR mediates transcription repression, we identified HEXIM1 as an N-CoR-interacting protein.
This finding led us to test whether the P-TEFb complex is regulated by acetylation. We demonstrate that CDK9
is an acetylated protein in cells and can be acetylated by p300 in vitro. Through both in vitro and in vivo assays,
we identified lysine 44 of CDK9 as a major acetylation site. We present evidence that CDK9 is regulated by
N-CoR and its associated HDAC3 and that acetylation of CDK9 affects its ability to phosphorylate the CTD of
pol II. These results suggest that acetylation of CDK9 is an important posttranslational modification that is
involved in regulating P-TEFb transcriptional elongation function.
Transcription by RNA polymerase II (pol II) is a multistep
process including preinitiation, initiation, promoter clearance,
elongation, and termination (48). Phosphorylation of the car-
boxy-terminal domain (CTD) of the largest subunit of pol II
plays a critical role in transition from transcriptional initiation
to elongation as well as in coordinating transcription elonga-
tion and RNA maturation (7, 30). P-TEFb, a positive tran-
scription elongation factor originally identified based on its
ability to stimulate 5,6-dichloro-1--D-ribofuranosyl-benzimi-
dazole-sensitive transcription of long transcripts in vitro (36),
stimulates transcription elongation by preferentially phospho-
rylating Ser2 of the heptapeptide repeat of the CTD of the
largest subunit of pol II (35). P-TEFb is a heterodimeric com-
plex comprised of cyclin-dependent kinase 9 (CDK9) and a
regulatory cyclin subunit of the T family, namely T1, T2, or K1
(13, 43). CDK9 is a cdc2-related, ubiquitously expressed kinase
protein (8). P-TEFb also enhances transcriptional elongation
by phosphorylating and counteracting the inhibitory factors
DSIF and NELF (5, 24, 51, 54).
In addition to its function as a global transcriptional elon-
gation factor important for most pol II transcription (3, 47),
activation of CDK9 kinase activity has also been linked to
specific events such as human immunodeficiency virus (HIV)
replication (20, 65), cardiac hypertrophy (45), and activation of
lymphocytes (19). In this regard, P-TEFb is also known as
TAK, an HIV Tat-associated kinase (20). Regulation of HIV
transcription is primarily mediated by the HIV Tat protein,
which recruits TAK/P-TEFb to enhance productive elongation
of viral transcripts (11, 12, 64). Activation of P-TEFb induces
heart hypertrophy in transgenic mice and induces myocyte
enlargement in tissue culture (44, 46).
As a complex important for pol II transcription, regulation
of the kinase activity of P-TEFb is a subject of intensive study.
Biochemical experiments suggest that cellular P-TEFb exists in
two forms, the active heterodimeric CDK9/cyclin T and an
inactive form containing the 7SK small nuclear RNA and
HEXIM1 protein (37, 41, 56, 57). In vitro studies have shown
that HEXIM1 binds to 7SK first, and this interaction allows the
subsequent association of 7SK and HEXIM1 with P-TEFb,
leading to sequestration of P-TEFb into an inactive complex
(10, 33). Contrary to this negative regulation, recent studies
indicate that the bromodomain protein Brd4 positively regu-
lates P-TEFb kinase activity (26, 55). Brd4 interacts with P-
TEFb through its double bromodomain, and this interaction
enhances P-TEFb-dependent phosphorylation of the pol II
CTD and transcriptional activation (26, 55).
N-CoR and its related SMRT protein were identified ini-
tially as corepressors for nuclear receptors such as thyroid
hormone receptors (TR) and retinoic acid receptors (RAR)
(4, 21). Subsequent studies have implicated these proteins
in repression by many different transcription factors, includ-
ing Mad/Mxi, BCL6/LAZ3, ETO, and CBF (for a review,
see reference 14). Repression mediated by SMRT and N-
CoR is sensitive to trichostatin A (TSA), a histone deacetylase
(HDAC) inhibitor, suggesting a dependence on HDAC activity
for repression (6, 18, 53). Consistent with this observation,
SMRT and N-CoR have been reported to associate with a
number of HDACs (18, 22, 29, 39). However, biochemical
studies have provided compelling evidence that both SMRT
and N-CoR exist in stable protein complexes containing mainly
HDAC3, GPS2, and TBL1 (transducin beta-like protein 1) and
TBLR1 (TBL1-related protein) (17, 32, 52, 58, 62). HDAC3 is
required, at least in the case of the thyroid hormone receptor,
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for transcriptional repression mediated by SMRT and N-CoR
(23, 58).
To better understand the biological function of N-CoR, we
have used a biochemical approach to purify and identify N-
CoR-associated proteins (32, 58, 59). Among the N-CoR-as-
sociated proteins, we identified HEXIM1. We found that a
subfraction of N-CoR is associated with P-TEFb. This finding
has led us to test whether the P-TEFb complex is regulated by
acetylation. We demonstrate that CDK9 is acetylated in cells
and present evidence that acetylation of CDK9 enhances its
ability to phosphorylate the CTD of pol II and promotes tran-
scriptional elongation.
MATERIALS AND METHODS
Plasmids and constructs. The HIV-1 long terminal repeat (LTR)-based lucif-
erase reporter G5-83-HIV-luc contains the LTR sequences from 83 to 82,
with five GAL4 binding sites inserted at position 83 (34), and was kindly
provided by L. Lania (University of Naples Federico II, Naples, Italy). The
CDK9 mutants (K44R, K48/49R, and K44/48/49R) were generated by site-di-
rected mutagenesis based on pcDNA3-CDK9 and were kindly provided by M.
Sano (Baylor College of Medicine). The wild-type and mutant CDK9 were then
cloned into pSG5-Flag for transient transfection, pCMV-GAL4-DBD (DNA
binding domain) for expression as Gal(DBD) fusion proteins, and pcDNA5/
FRT/TO for generating Tet-inducible stable cell lines. In addition, the full-length
CDK9 was cloned into pGEX-4T1 for preparation of glutathione S-transferase
(GST)–CDK9 from bacteria. GST-CDK9N and its related mutants were gener-
ated by cloning the corresponding DNA sequences encoding the first 55 amino
acids (aa 1 to 55) of CDK9 into pGEX4T1. The coding region of human
HEXIM1 was amplified by reverse transcription-PCR and cloned into pGEX-
4T1 or pCMV-Gal4-DBD.
Identification of HEXIM1 as an N-CoR-associated protein. The purification of
the N-CoR complex from HeLa nuclear extracts was previously reported (59).
The presence of two peptides derived from HEXIM1 was not recognized at the
time and was identified when the data were reexamined later on.
IP, Western blotting, and gel filtration. Immunoprecipitation (IP) and West-
ern blot analysis (IP-Western) with HeLa nuclear extracts was essentially as
described previously (31). For IP-Western analysis using whole-cell extracts,
HeLa cells or other cells were washed with phosphate-buffered saline (PBS) two
times and lysed with ice-cold EBC buffer (20 mM Tris-HCl, pH 8.0, 125 mM
NaCl, 2 mM EDTA, and 0.5% NP-40) with protease inhibitors for 15 min. The
lysates were centrifuged at 13,000 rpm for 15 min at 4°C to remove cell debris.
The whole-cell extracts were precleared with protein A/G-conjugated Sepharose
beads for 2 h at 4°C with gentle agitation. After a high-speed centrifugation to
remove beads, the extracts were incubated overnight at 4°C with rotation with a
specific antibody as indicated. The protein A/G-conjugated Sepharose beads
were then added and incubated at 4°C for another 1 h. The immune complexes
were collected and washed extensively with immunoprecipitation washing buffer.
The samples were resolved by sodium dodecyl sulfate–7.5% polyacrylamide gel
electrophoresis (SDS–7.5% PAGE) or SDS–10% PAGE and transferred to
nitrocellulose membranes for subsequent Western blot analysis. For multiple
rounds of blotting, the membranes were stripped in stripping buffer (100 mM
-mercaptoethanol, 2% SDS, and 62.5 mM Tris-Cl, pH 6.7) for 30 min at 50°C.
The antibodies against N-CoR and HDAC3 were as described previously (59),
and antibody against HEXIM1 was raised against GST-HEXIM1. Anti-Flag
monoclonal antibody was purchased from Sigma and CDK9, and cyclin T1
antibodies were from Santa Cruz Biotechnology.
Gel filtration analysis of HeLa nuclear extracts using a Superose 6 column was
performed as previously described (58). Prior to gel filtration analysis, the HeLa
nuclear extracts were treated either with or without RNase A at room temper-
ature for 30 min.
CTD kinase assay. Immune complex kinase assays for P-TEFb were per-
formed essentially as described previously (44), using monoclonal antibody
against FLAG or CDK9. Kinase assays were performed by adding 25 l of kinase
buffer containing 50 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 5 mM dithiothreitol,
2.5 mM MnCl2, 5 M ATP, 5 Ci [-32P]ATP, and 200 ng GST-CTD to the
beads and incubation at room temperature with rotation for 60 min. The com-
plexes were resolved by SDS-PAGE, and CTD phosphorylation was visualized by
autoradiography.
GST pulldown assay. GST pulldown assays were done essentially as previously
described (61). In brief, both GST and GST-HEXIM1 fusion proteins were
expressed in BL21 Escherichia coli cells, and equal amounts of each protein were
immobilized onto glutathione-Sepharose 4B beads (Amersham Biosciences).
The beads were incubated for 2 h at 4°C with 35S-labeled SMRT, N-CoR,
HDAC3, TBL1 and TBLR1, or N-CoR fragments synthesized using a TNT in
vitro transcription/translation kit (Promega) according to the manufacturer’s
instructions. The beads were washed five times with washing buffer (20 mM
Tris-HCl, 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 0.1% NP-40 with
protease inhibitors). The samples were then separated by SDS-PAGE and visu-
alized by autoradiography.
Cell culture and siRNA. HeLa cells and 293T cells were routinely maintained
in Dulbecco’s modified Eagle medium (Invitrogen Inc.) supplemented with 10%
fetal bovine serum and 1% antibiotics at 37°C under 5% CO2. For the small
interfering RNA (siRNA) experiments, HeLa cells were seeded the night before
transfection at such a density that cells reach about 30 to 40% confluence by the
time of transfection. siN-CoR and siHDAC3 were previously described (58).
siHEXIM1 (AAGUUCGACGAGAAACAGA) was synthesized by Dharmacon
Research. siHEXIM1 (20 nM) was used for transfection using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. siRNA-trans-
fected cells were cultured for 3 days and then transfected with reporter DNA and
CDK9 expression constructs as indicated in the figure legends. The efficiency of
the siRNA knockdown was determined at the end of each experiment by West-
ern blot analysis using corresponding specific antibodies.
Generation of the CDK9 inducible stable cell line. Inducible stable 293 cell
lines expressing Flag-CDK9 or CDK9 mutants (K44R, K48/49R, and K44/48/
49R, respectively) were generated using the Flp-In-T-REx system from Invitro-
gen. The wild-type CDK9 or CDK mutants were cloned into pcDNA5/FRT/TO
expression vector and transfected into Flp-In-293 host cells, and the stable cells
with integrated CDK9 or mutant expression constructs were selected according
to the manufacturer’s instructions (Invitrogen).
RPA. RNase protection assay (RPA) was performed essentially as described
previously, with minor modifications (34). In brief, total RNAs were isolated
from transfected cells 24 h posttransfection. Approximately 30 g of total RNA
for each sample was used for the RNase protection assay. To make the HIV LTR
probe (120 bp), the 175-bp-long PCR amplification fragment was produced using
G5-83-HIV-luc as a template by the primer pair of RPA1 (AACCTTGGCACT
ATGTTACTGGGTCTCTCTGGTT) and RPA2 (TAATACGACTCACTATG
GGTCCTATGGCATAAGTCTTCCATGGTGGCTTTAC) that also contains a
T7 promoter. The T7 polymerase was used to produce [-32P]UTP-labeled RNA
probe according to the MAXIscript in vitro transcription kit (Ambion). The
RNase protection assay was performed using the RPA III RNase protection
assay kit (Ambion). The protected fragments were separated on a 10% poly-
acrylamide–8 M urea sequencing gel and analyzed using the Molecular Dynamics
PhosphorImager System.
In vivo acetylation assay. For metabolic labeling of acetylated proteins in
HeLa cells, HeLa cells (2  108) were washed twice with cold PBS, resuspended
in Dulbecco’s modified Eagle’s medium-based labeling medium (1 mCi of
[3H]sodium acetate/ml and 2 M trichostatin A [TSA] in 5 ml of DMEM) and
incubated at 37°C for 1 h. Cells were washed twice with cold PBS and lysed with
the EBC buffer. After a high-speed centrifugation to remove cell debris, the
extracts were prepared and processed for immunoprecipitation with antibody
against CDK9, HEX1M1, or cyclin T1. For metabolic labeling of stable 293
inducible Flag-CDK9 or mutant cell lines, cells were first induced to express
Flag-CDK9 or mutants with 1 g/ml doxycycline overnight and then metaboli-
cally labeled with [3H]sodium acetate as described above. The cell lysates were
prepared either as described above (see Fig. 3B) or with radioimmunoprecipi-
tation assay (RIPA) buffer (see Fig. 4D), centrifuged to remove insoluble debris,
and used for IP using M2 agarose beads. The immunopurified Flag-CDK9 or its
mutants were resolved on SDS–10% PAGE, fixed with 7% glacial acetic acid and
25% methanol for 30 min, and enhanced with a commercial fluorography en-
hancing solution (Amplify) (Amersham Pharmacia Biotech) for 30 min. Gels
were then dried and subjected to autoradiography at 70°C for 7 to 14 days.
In vitro acetylation assay. In vitro acetylation was performed using either
recombinant GST-CDK9, GST-CDK9N (residues 1 to 55), GST-CDK9N mu-
tants, or immunoprecipitated CDK9 as substrate. Bacterially expressed p300
fragment (residues 1195 to 1810) was used as acetyltransferase, and the acety-
lation reactions were essentially as described previously (31). Reaction products
were resolved by SDS-PAGE. Gels were stained with Coomassie brilliant blue,
destained, and then treated with Amplify at room temperature for 30 min, dried,
and subjected to autoradiography at 70°C for 2 to 15 days.
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RESULTS
HEXIM1 as an N-CoR-interacting protein. Through a com-
bination of conventional chromatography and antibody affinity
purification, we had purified the N-CoR complex(es) from
HeLa nuclear extracts and identified TBL1/TBLR1 as its as-
sociated proteins through mass spectrometry (59). Careful ex-
amination of the large number of peptides deriving from the
TBL1/TBLR1 band identified two peptides belonging to
HEXIM1 protein (Fig. 1A). Because HEXIM1 was known to
associate with and regulate P-TFEb (37, 57), a positive tran-
scriptional elongation factor, the association of N-CoR with
HEXIM1 raised the possibility that, in addition to histone
deacetylation, N-CoR complex may repress transcription
through negative regulation of P-TEFb. To confirm its associ-
ation with N-CoR, we raised an antibody against GST-
HEXIM1, and the specificity of this antibody was confirmed by
IP-Western analysis (Fig. 1B). When this antibody was used
for IP-Western analysis, we found that HEXIM1 was detected
in IP of HeLa nuclear extracts with antibodies against N-CoR
or HDAC3 but not a control rabbit anti-mouse immunoglob-
ulin G (Fig. 1C). In the same IP, we found that HDAC3 but
not HDAC1/2 was coprecipitated with HEXIM1 (data not
shown; also see Fig. 2A).
To further substantiate the interaction between HEXIM1
and N-CoR complex, we next tested if tethering HEXIM1 to
DNA through a Gal4 DNA binding domain was able to recruit
N-CoR complex to DNA. We transfected a luciferase reporter
(4XUAS-TK-luc) with Gal4-HEXIM1 or control Gal4-DBD
into HeLa cells and carried out chromatin immunoprecipita-
tion (ChIP) assays as described previously (61). The results in
Fig. 1D demonstrate that, while both Gal4-DBD and Gal4-
HEXIM1 bound to the reporter DNA (lane 6), N-CoR and
HDAC3 were only detected in the presence of Gal4-HEXIM1.
The weak signal from HEXIM1 antibody for Gal-DBD is likely
the nonspecific background, since it was not detected when less
HEXIM1 antibody was used (data not shown). Thus, tethering
HEXIM1 to DNA is sufficient to recruit N-CoR complex,
demonstrating further an interaction between HEXIM1 and
N-CoR complex.
We next analyzed which subunit of the N-CoR complex
interacts with HEXIM1 using an in vitro GST pulldown assay.
We found that in vitro-translated N-CoR bound to GST-
HEXIM1, whereas no binding of TBL1 and TBLR1 was de-
tected (Fig. 1E). A weak binding was also detected for
HDAC3. In addition, the N-CoR-related SMRT protein also
exhibited a weak binding in this assay. Thus, the in vitro pull-
down assay indicates that HEXIM1 likely associates with N-
CoR complex through a direct interaction with N-CoR. Con-
sistent with this idea, we have further mapped the HEXIM1
interaction domain of N-CoR to the N-CoR RD1 region
(Fig. 1F).
Association of N-CoR complex with CDK9. Given that
HEXIM1 associates with and negatively regulates P-TEFb, we
next tested if N-CoR complex also interacts with P-TEFb. We
performed IP-Western analysis using HeLa nuclear extracts
and antibodies against HEXIM1, N-CoR, HDAC3, and
CDK9. We found that, like HEXIM1, a low level of CDK9 was
coprecipitated with N-CoR and HDAC3 (Fig. 2A). Further-
more, HDAC3 was also detected in IP with anti-CDK9 anti-
body. Consistent with previous reports (37, 57, 58), CDK9 was
abundantly coprecipitated with HEXIM1, and HDAC3 was
readily coprecipitated with N-CoR. These results suggest that
a subfraction of N-CoR/HDAC3 complex was associated with
FIG. 1. N-CoR interacts with HEXIM1. (A) HEXIM1 copurified
with N-CoR from HeLa nuclear extracts. The purification of N-CoR
complex was reported previously (59). The identity of the protein(s) in
each band was determined by mass spectrometry. Two peptides de-
rived from the TBL1/TBLR1 band were found to match with
HEXIM1. (B) A rabbit anti-HEXIM1 antibody was raised against
GST-HEXIM1. IP-Western analysis was performed using HeLa nu-
clear extract and anti-HEXIM1 antibody or preimmune serum. WB,
Western blot. (C) Reciprocal IP showing the association of HEXIM1
with N-CoR complex. HeLa nuclear extracts were used for IP using
antibodies as indicated, and the presence of HEXIM1 was detected by
Western blot analysis. Input, 10% extract used for IP. The control ()
lane was IP using rabbit anti-mouse immunoglobulin G. (D) Gal-
HEXIM1 recruited N-CoR complex to reporter DNA bearing Gal-
DBD binding sites. Gal-HEXIM1 or control Gal-DBD(aa1-147) was
transfected with the 4XUAS-TK-luc reporter into HeLa cells, and 24 h
after transfection the association of N-CoR complex with the reporter
DNA was analyzed by ChIP assay. The weak HEXIM1 signal from the
control Gal-DBD sample is likely nonspecific. Note that N-CoR and
HDAC3 were found to associate with the reporter DNA only in the
presence of Gal-HEXIM1. (E) Analysis of the interaction between
HEXIM1 and individual subunits of N-CoR/SMRT complexes using in
vitro GST pulldown. Each subunit of the N-CoR complex was in vitro
synthesized and labeled with [35S]methionine. The binding to GST-
HEXIM1 was detected by autoradiography. (F) Each N-CoR fragment
was in vitro synthesized and labeled with [35S]methionine. The binding
to GST-HEXIM1 was detected by autoradiography.
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HEXIM1/P-TEFb. In support of association with P-TEFb
complex, cyclin T1 could be detected in IP with antibody
against N-CoR or HDAC3 (data not shown). The association
of N-CoR with P-TEFb was further demonstrated by the result
that both N-CoR and HEXIM1 were specifically coprecipi-
tated from the HeLa cell extracts overexpressing a Flag-tagged
CDK9 (Fig. 2B). The association between N-CoR and P-TEFb
is at least in part dependent on 7SK small nuclear RNA,
because addition of RNase A to HeLa nuclear extracts sub-
stantially reduced the amount of CDK9 coprecipitated with
HEXMI1 and CDK9 but had no effect on IP of CDK9 itself
(Fig. 2C). Finally, when HeLa nuclear extracts were fraction-
ated using a Superose 6 sizing column, we found that there was
an overlap between fractions containing N-CoR/HDAC3 com-
plex and HEXIM1/P-TEFb (Fig. 2D). RNase A treatment of
HeLa nuclear extract resulted in significant change in the frac-
tionation pattern of CDK9 and HEXIM1 (Fig. 2D, lower
panel), suggesting that the large CDK9/HEXIM1 complex(es)
contains an RNA component, most likely 7SK. Taken to-
gether, these results indicate that a subfraction of cellular
HEXIM1/P-TEFb is associated with N-CoR/HDAC3 complex.
CDK9 can be acetylated both in vivo and in vitro. N-CoR/
HDAC3 is well documented as a corepressor complex that
represses transcription through its ability to deacetylate his-
tones in chromatin (17, 32, 52, 58, 62). Given the interaction
between N-CoR/HDAC3 and P-TEFb complex, we hypothe-
sized that P-TEFb complex may be regulated by acetylation
and deacetylation. To test this possibility, we metabolically
labeled the acetylated proteins in HeLa cells with [3H]sodium
acetate for 1 h. We then immunoprecipitated P-TEFb complex
from the cellular extracts and determined if any component of
the cellular P-TEFb complex was acetylated by autoradiogra-
phy. As shown in Fig. 3A, we found that antibodies against
both cyclin T1 and CDK9 precipitated an acetylated protein
with an expected size of CDK9. Consistent with an interaction
between HEXIM1 and P-TEFb, the same protein was also
precipitated with anti-HEXIM1 antibody (Fig. 3A). To ensure
that this acetylated protein is CDK9, we established an induc-
FIG. 2. Subfraction of P-TEFb associates with the N-CoR complex. (A) CDK9 coimmunoprecipitated with N-CoR complex. HeLa nuclear
extracts were used for IP using antibodies as indicated, and Western blotting (WB) was performed with anti-HEXIM1, -HDAC3, and -CDK9,
respectively. (B) N-CoR and HEXIM1 coimmunoprecipitated with Flag-tagged CDK9. Whole-cell extracts were prepared from HeLa cells
transfected with or without Flag-CDK9, and IP was performed using anti-Flag M2 agarose beads. The co-IP of N-CoR and HEXIM1 was then
detected by Western blotting. (C) 7SK RNA is likely required for the association between N-CoR and P-TEFb. HeLa nuclear extracts (NE) were
treated with or without RNase A for 30 min and then used for IP-Western analysis. (D) N-CoR complex partially cofractionated with CDK9 and
P-TEFb in gel filtration experiments. HeLa nuclear extracts were treated with or without RNase A and fractionated through a fast-protein liquid
chromatography Superose 6 sizing column. Different fractions were analyzed by Western blotting using antibodies as indicated. The peak fractions
for molecular size markers are indicated.
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ible Flag-CDK9 stable cell line using the 293 Flp-In system
from Invitrogen. This cell line was subjected to overnight in-
duction of Flag-CDK9 with doxycycline (1 g/ml), followed by
metabolic labeling with [3H]sodium acetate. Immunoprecipi-
tation with anti-Flag antibody followed by autoradiography
clearly detected an acetylated protein with the expected size of
Flag-CDK9 (Fig. 3B, left panel). Under similar conditions,
purification of Flag-CDK9 from control unlabeled cells yielded
a Flag-CDK9 complex containing cyclin T1, HSP90, HSP70,
and CDC37 and other known CDK9-associated proteins (Fig.
3B, right panel). Together these results indicate that in the
P-TEFb complex only CDK9 is acetylated in vivo.
Having established that CDK9 within the P-TEFb complex
is acetylated in vivo, we next tested if CDK9 could be acety-
lated in vitro. We isolated Flag-CDK9 from our Flag-CDK9
inducible cell line and subjected it to acetylation by recombi-
nant p300HAT. The results in Fig. 3C show that an acetylated
protein was detected from samples derived from the Flag-
CDK9 stable cell line (lane 2) but not from the control paren-
tal cell line (lane 1). The size of these acetylated proteins again
matched perfectly with Flag-CDK9. As previously reported,
p300HAT underwent autoacetylation in these reactions (50).
Taken together, these results show that CDK9 is an acetylated
protein in vivo and can be acetylated by p300 in vitro.
Identification of CDK9 acetylation sites. To identify poten-
tial acetylation sites in CDK9, we decided to first map the
CDK9 acetylation sites catalyzed by p300HAT in vitro. For this
purpose, we expressed and purified GST-CDK9 fusion protein
from bacteria and tested if it could be acetylated by p300HAT.
The autoradiography results in Fig. 4A revealed a strongly
acetylated band in the reaction with GST-CDK9. However,
careful comparison with protein bands in the Coomassie stain-
ing gel indicated this acetylated band did not match with the
full-length GST-CDK9 but with a smaller-sized protein band
we termed GST-CDK9S. By Western blot analysis using anti-
GST antibody, we verified that this protein contained GST
(data not shown). Based on its size and the presence of GST,
we surmised this acetylated protein was a spontaneously de-
graded GST-CDK9 containing a portion of CDK9 N-terminal
sequence. As a specificity control, we found that both GST and
GST-HEXIM1 were not acetylated by p300HAT under the
same experimental condition. As an internal control for the
acetylation reaction, p300HAT domain was autoacetylated to
the same extent in all three reactions. Since the data in Fig. 3C
show that Flag-CDK9 was acetylated by p300HAT in vitro, the
lack of acetylation for the full-length GST-CDK9 by p300HAT
in this experiment was likely a consequence of steric hindrance
caused by the presence of GST. The acetylation site(s) in the N
terminus of CDK9 was likely exposed when a large portion of
CDK9 was spontaneously deleted from GST-CDK9. Neverthe-
less, this fortuitous data suggested to us that CDK9 is likely
acetylated at its N terminus.
To search for potential acetylation sites in the N terminus of
CDK9, we first aligned CDK9 sequences from different organ-
isms (Fig. 4B). This analysis revealed three evolutionally con-
served lysine (K) residues at positions 44, 48, and 49 of human
CDK9. To test if these sites could be acetylated by p300 in
vitro, we generated GST-CDK9N(aa1-55) fusion protein as
well as the fusion proteins containing specific K-to-arginine
(R) mutations at the sites indicated. We chose K-to-R muta-
tion because this change eliminates acetylation but likely main-
tains the protein conformation. When these GST fusion pro-
teins were subjected to acetylation by p300HAT, we found that
the K48/49R mutant was less efficiently acetylated and the
K44/48/49R mutant was poorly acetylated (Fig. 4C). Like the
K44/48/49R mutant, the K44R mutant was also poorly acety-
lated, suggesting that K44 is the major site acetylated by
p300HAT in vitro. Thus, our in vitro studies identified within
CDK9N(aa1-55) K48/49 as potential sites and K44 as the ma-
jor site for acetylation by p300HAT.
K44 is the major acetylation site of CDK9 in vivo. To test if
the acetylation occurs in cells at the sites identified in vitro, we
generated stable cell lines expressing Flag-tagged K44R, K48/
49R, or K44/48/49R CDK9 mutant, respectively. These cell
lines were subjected to in vivo metabolic labeling as described
FIG. 3. In vivo and in vitro acetylation of CDK9. (A) CDK9 is an
acetylated (Ac) protein in HeLa cells. The acetylated proteins in HeLa
cells were metabolically labeled with [3H]sodium acetate for 1 h. The
P-TEFb complex was isolated from the whole-cell extract by IP using
anti-cyclin T1, -CDK9, or -HEXIM1 antibody and resolved by SDS–
10% PAGE. The acetylation status of P-TEFb was revealed by auto-
radiography. The size of the acetylated protein matched with CDK9.
(B) A stable Flag-CDK9 cell line was metabolically labeled with
[3H]sodium acetate, and Flag-CDK9 was isolated from the whole-cell
extract using anti-Flag M2 beads. The acetylation of Flag-CDK9 was
detected by autoradiography following SDS-PAGE. As a specificity
control, the extract was also immunoprecipitated using rabbit anti-
mouse immunoglobulin G (). The left panel shows Flag-CDK9 com-
plex purified from the control unlabeled cells revealed by Coomassie
staining. The identities of the proteins were determined by mass spec-
trometry analysis. (C) Flag-CDK9 was isolated from the whole-cell
extract as described above and subjected to in vitro acetylation by
p300HAT (HAT domain). The whole-cell extract derived from the
parent 293 Flp-In cells () was also subjected to purification using
anti-Flag M2 beads and used as a negative control. The acetylation of
Flag-CDK9 was detected by autoradiography following SDS-PAGE.
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FIG. 4. CDK9 is mainly acetylated at the site of K44. (A) p300HAT acetylated the CDK9 N-terminal sequence in vitro. The recombinant GST,
GST-CDK9, and GST-HEXIM1 were incubated with p300HAT in acetylation reactions, and the resulting acetylated proteins were resolved by
SDS-PAGE and visualized by autoradiography. Note that the size of the acetylated protein in the GST-CDK9 lane matched with a short protein
(GST-CDK9S) but not with the full-length GST-CDK9. Ac-p300, acetylated p300. (B) The alignment of CDK9 sequences reveals highly conserved
K residues in the N-terminal domain. The accession numbers for each of the proteins in the alignment are as follows: NP_001252 (Homo sapiens),
NP_570930 (Mus musculus), AAH55634 (Danio rerio), AAH45274 (Xenopus laevis), AAM50669 (Drosophila melanogaster), and XP_392973 (Apis
mellifera). The conserved K residues are indicated by arrows. (C) The CDK9 N-terminal sequence (aa 1 to 55) was expressed as a GST fusion
(GST-CDK9N). Each of the conserved K residues was mutated to R individually or in combination as indicated. The resulting GST fusion proteins
were purified from bacteria and subjected to in vitro acetylation with p300HAT using [3H]acetyl-coenzyme A as substrate. The upper panel shows
the results of acetylation detected by autoradiography, whereas the lower panel shows recombinant GST, GST-CDK9N, and its related mutants
revealed by Coomassie staining. (D) Stable cell lines expressing wild-type (WT) Flag-CDK9 or Flag-CDK9 bearing K44R, K48/49R, or K44/48/49R
mutation were metabolically labeled with [3H]sodium acetate, and the whole-cell extracts were prepared with RIPA buffer. Flag-CDK9 and each
mutant CDK9 were isolated from the whole-cell extracts and divided into two aliquots, one for detection of CDK9 acetylation by autoradiography
and one for quantitating CDK9 proteins by Western blotting (WB). (E) The results shown in panel D were quantified and are shown as relative
levels of acetylation of different CDK9 mutants in comparison to the wild-type CDK9.
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above. To ensure that the observed acetylated protein was
indeed Flag-tagged CDK9 or mutants, the cell extracts were
prepared with stringent RIPA buffer and used for IP with
anti-Flag M2 beads. The results depicted in Fig. 4D show that
K48/49R mutation resulted in 50% reduction of acetylation.
The K44R mutant displayed a more significant reduction of
acetylation (75%), whereas the level of acetylation of K44/
48/49R mutant was similar to that of K44R. As a control,
Western blot analysis using anti-Flag antibody showed that the
difference in the levels of acetylation was not due to the dif-
ference in the levels of proteins. Thus, the in vivo labeling
experiment demonstrated the critical role for K44 in CDK9
acetylation, in full agreement with our in vitro data in Fig. 4C.
Since the K44/48/49R mutant still retained 20 to 30% of
acetylation compared to Flag-CDK9 (Fig. 4D), CDK9 was also
acetylated at another unidentified site(s).
Acetylation on K44 of CDK9 affects P-TEFb kinase activity.
The above results identified K44 as the major acetylation site
of CDK9. To examine how K44 acetylation affects CDK9 func-
tion, we isolated the P-TEFb complex from the inducible stable
cell lines expressing either the wild type or K44R mutant using
anti-Flag M2 beads and assayed their kinase activity using
GST-CTD substrate as described previously (44). The results
in Fig. 5A show that the kinase activity of the K44R mutant was
significantly crippled compared to that of the wild-type CDK9.
Since the kinase activity of CDK9 is dependent on its associ-
ation with the cyclin T subunit (42, 43), we performed IP-
Western analysis to test if K44R mutation affected the associ-
ation between CDK9 and cyclin T1. The results shown in Fig.
5B indicate that K44R mutation did not affect the interaction
between CDK9 and cyclin T1. In addition, the K44R mutant
exhibited normal association with HEXIM1, thus excluding
aberrant association with HEXIM/7SK as an explanation for
the reduced kinase activity (Fig. 5B). Given that K44 is acety-
lated in vivo and K-to-R mutation is likely to maintain CDK9
conformation but eliminate acetylation, we suggest that acet-
ylation on K44 of CDK9 positively regulates P-TFEb kinase
activity.
To further substantiate that acetylation regulates P-TEFb
kinase activity, we next tested if the P-TEFb kinase activity is
modulated by HDACs. For this purpose, Flag-CDK9 was co-
expressed in HeLa cells with or without HDAC1 or HDAC3 by
transfection. Flag-CDK9 was then isolated from the trans-
fected cells, and the kinase activity was assayed using GST-
CTD as substrate as described above. A representative result
in Fig. 5C shows that Flag-CDK9 isolated from cells expressing
FIG. 5. CDK9 acetylation positively regulates its kinase activity. (A) The K44R mutation in CDK9 significantly impaired its kinase activity. The
P-TEFb complex was isolated from the whole-cell extracts expressing Flag-CDK9 or Flag-CDK9(K44R) mutant and divided into two aliquots, one
for a kinase activity assay using GST-CTD as substrate and [-32P]ATP and the other for Western blot (WB) analysis. (B) IP-Western analysis
showing that K44R mutation did not affect the association of CDK9 with cyclin T1 and HEXIM1. (C) Expression of HDAC1 or HDAC3 reduced
CDK9 kinase activity. Flag-CDK9 was cotransfected without or with an HDAC1 or HDAC3 expression plasmid into HeLa cells, and the
Flag-CDK9-containing P-TFEb complex was recovered from the whole-cell extracts using anti-Flag M2 beads and assayed for phosphorylation of
GST-CTD as described above. The levels of phosphorylation were quantified using a densitometer. The Western blot analysis of Flag-CDK9
showed that a comparable amount of Flag-CDK9 was recovered from each sample. (D) TSA treatment abolished the association between CDK9
and HDAC3. HeLa cells were treated with or without TSA (330 nM) for 12 h, and the association between CDK9 and HDAC3 was analyzed by
IP-Western analysis. WT, wild type.
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HDAC1 or HDAC3 exhibited reduced kinase activity toward
GST-CTD. Control Western blot analysis demonstrated that
an equal amount of CDK9 was isolated and used in the kinase
reactions (Fig. 5C, lower panel). Interestingly, in this experi-
ment HDAC1 inhibited CDK9 kinase activity more than
HDAC3, although endogenous HDAC1 was not found to as-
sociate with CDK9 (see Fig. 5D). This discrepancy could be
explained if overexpression of HDAC1 allowed HDAC1 to
deacetylate CDK9 and by the possibility that overexpression of
HDAC3 may not significantly increase HDAC3 activity, since
the HDAC3 activity is dependent on its incorporation into the
SMRT/N-CoR complex (16, 52, 62). As additional evidence
that CDK9 is regulated by HDAC3, we found that TSA treat-
ment of HeLa cells led to dissociation of endogenous CDK9
from HDAC3 (Fig. 5D). This result suggests that HDAC3 is
likely directly involved in the interaction with P-TEFb com-
plex. Together these results support that the kinase activity of
P-TEFb is regulated by acetylation of the CDK9 subunit.
Acetylation on K44 of CDK9 affects P-TEFb transcriptional
elongation activity. Previous studies indicated that transcrip-
tion from the HIV LTR gives rise to primarily short, abortive
transcripts 55 to 70 nucleotides in length in the absence of Tat
activator (27, 34). Tat is known to recruit P-TEFb, which in
turn promotes transcriptional elongation and production of
full-length polyadenylated transcripts. Importantly, direct tar-
geting of CDK9 or CycT1 as a Gal4(DBD) fusion protein to a
reporter driven by the HIV LTR promoter activates transcrip-
tion primarily by promoting elongation, and the kinase activity
of CDK9 is strictly required for this activity (1, 34, 49). We thus
used this system to assay if K44R mutation impaired CDK9
transcriptional elongation activity. Consistent with previous
results (34), we found that expression of Gal-CDK9 enhanced
the transcription 4.6-fold from an HIV LTR-driven (G5-83-
HIV-luc) reporter bearing five Gal4 binding sites (Fig. 6A).
Under the same conditions, the K44R mutant had only 30%
of the wild-type CDK9 transcriptional activity (Fig. 6A). West-
ern blot analysis revealed a similar level of Gal-CDK9 and
Gal-K44R mutant, indicating that K44R mutation significantly
reduced its ability to enhance transcriptional elongation.
To gain further evidence that the reduced transcriptional
activity of K44R mutant is linked to its defect in K44 acetyla-
tion, we compared the effect of expression of HEXIM1 or
HDAC3 on the transcriptional activity of Gal-CDK9 and Gal-
K44R mutant. As shown in Fig. 6B, expression of either
HEXIM1 or HDAC3 reduced the transcriptional activity of
Gal-CDK9. However, expression of HEXIM1 or HDAC3 had
a minimal effect on the transcriptional activity of the Gal-K44R
mutant. Western blot analysis detected a comparable level of
Gal-CDK9 or Gal-K44R mutant from each sample. This result
suggests that K44 of CDK9 is required for HDAC3 to inhibit
CDK9 transcriptional activity, implying that HDAC3 inhibits
CDK9 transcriptional activity mainly through deacetylation of
K44.
To test if endogenous N-CoR/HDAC3 repressed CDK9
transcriptional activity, we made use of siRNA specific for
N-CoR or HDAC3. We found that knockdown of either N-
CoR or HDAC3 resulted in increased transcriptional activity
for Gal-CDK9 (Fig. 6C). The knockdown of N-CoR or
HDAC3 by its corresponding siRNA was confirmed by West-
ern blot analysis (Fig. 6C, lower panel). Consistent with
HEXIM1 as a negative regulator of P-TEFb (57), we found
that knockdown of HEXIM1 also led to increased transcrip-
tional activity for Gal-CDK9 (Fig. 6D).
To directly examine that K44R mutation impaired the tran-
scriptional elongation function of CDK9, we performed the
RNase protection assays depicted in Fig. 7A to measure both
long transcripts and abortive short transcripts as described
previously (34). A representative result in Fig. 7B shows that
there was no significant difference between two samples in the
levels of short transcripts. However, the level of long tran-
scripts was significantly lower for the sample derived from
Gal-K44R mutant-transfected cells. This result is consistent
FIG. 6. CDK9 transcriptional activity is negatively regulated by N-
CoR/HDAC3. (A) The CDK9 bearing K44R mutation exhibited re-
duced transcriptional activity when tethered to reporter DNA as a
Gal-DBD fusion protein. 293T cells were transfected with expression
vector for control Gal-DBD, Gal-CDK9, or Gal-K44R mutant and
G5-83-HIV-luc reporter as indicated. The luciferase activities were
determined, and results are presented as the means 	 standard errors
of three independent experiments. The expression of Gal-CDK9 fu-
sions was detected by Western blotting (WB) using anti-CDK9 anti-
body. (B) Expression of HEXIM1 or HDAC3 repressed the transcrip-
tional activity of the wild-type CDK9 but not the K44R mutant. The
results are presented as relative activities, with the value of Gal-CDK9
set as 1. Also shown is the level of Gal-CDK9 revealed by Western
blotting using anti-CDK9 antibody. (C) Knockdown of N-CoR or
HDAC3 enhanced the transcriptional activity of CDK9. HeLa cells
were treated with or without siN-CoR or siHDAC3 as indicated, fol-
lowed by transfection with Gal4-CDK9 and G5-83-HIV-luc reporter.
The knockdown of N-CoR or HDAC3 was verified by Western blot
analysis. (D) Knockdown of HEXIM1 enhanced the transcriptional
activity of CDK9. HeLa cells were treated with or without siHEXIM1
for two days before transfection with Gal4-CDK9 and G5-83-HIV-luc
reporter. The knockdown of HEXIM1 was verified by Western blot
analysis.
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with the previous data that CDK9 enhances transcription from
the HIV LTR reporter by promoting transcriptional elonga-
tion.
Targeting components of N-CoR complex to the HIV LTR
reporter suppresses transcriptional elongation. So far we
have shown that N-CoR complex interacts with P-TEFb and
potentially regulates CDK9 transcriptional elongation activ-
ity through deacetylation of CDK9. To test if N-CoR com-
plex could repress P-TEFb-dependent transcriptional elon-
gation, we tested if tethering components of N-CoR
complex to the G5-83-HIV-luc reporter inhibited the pro-
duction of long transcripts by RNase protection. The results
in Fig. 7C show that Gal-TBL1, Gal-TBLR1, and Gal-
HDAC3 all significantly inhibited the production of long
forms of transcripts but had much less effect on the short
transcripts. These results show a role for N-CoR complex in
repression of transcriptional elongation, presumably through its
inhibition of P-TEFb activity.
DISCUSSION
While histone acetylation clearly plays a critical role in tran-
scriptional regulation, growing evidence indicates that acetyla-
tion of non-histone proteins also plays a role in transcriptional
regulation. More and more proteins have been found to be
acetylated in vitro and/or in vivo, including general transcrip-
tional factors, transcription factors, chaperones, and many oth-
ers (for reviews, see references 15 and 63). In this study, we
found that a subfraction of N-CoR/HDAC3 complex is asso-
ciated with P-TEFb. We further showed that CDK9 is an
acetylated protein in vivo and can be acetylated by p300 in
vitro. Through both in vitro and in vivo experiments, we iden-
tified the highly conserved K44 of CDK9 as a major acetylation
site and demonstrated that a single K44R mutation crippled
CDK9 kinase activity. We also showed that the K44R mutation
significantly reduced the ability for CDK9 to enhance tran-
scriptional elongation from an HIV LTR promoter-driven re-
porter (Fig. 6A and 7B). Previous studies have shown that the
transcriptional activity of the HIV LTR promoter is primarily
regulated at the step of transcriptional elongation and that
targeting CDK9 to an HIV LTR promoter-driven reporter
activates transcription by promoting elongation in a CDK9
kinase-dependent manner (1, 27, 34, 49). Together our data
support a role for acetylation of K44 of CDK9 in control of
P-TEFb kinase and transcriptional elongation activity.
In this study we have also provided multiple lines of evi-
dence that N-CoR complex negatively regulates P-TEFb activ-
ity. First, we found that a subfraction of N-CoR complex is
associated with P-TEFb. Second, we showed that coexpression
of HDAC3 with CDK9 reduced the CDK9 kinase activity (Fig.
5C). Third, using transcriptional activation of the HIV LTR
promoter by Gal-CDK9 as a functional readout for P-TEFb
kinase and transcriptional elongation activity, we found that
overexpression of HDAC3 repressed and knockdown of
HDAC3 or N-CoR enhanced the P-TEFb activity (Fig. 6B and
C). It is noteworthy that overexpression of HDAC3 did not
repress the transcriptional activity of the CDK9 K44R mutant
(Fig. 6B). Since K44 is the major acetylation site of CDK9 and
CDK9 is the only acetylated protein in the P-TEFb complex,
this result suggests that N-CoR/HDAC3 is likely to repress
P-TEFb activity through deacetylation of K44 of CDK9. Fi-
nally, we showed that targeting subunits of N-CoR complex to
the HIV LTR-driven reporter also preferentially inhibited the
production of long transcripts (Fig. 7C). Since transcriptional
elongation from this reporter is dependent on P-TEFb, we
took these results as inhibition of P-TEFb activity by the N-
CoR complex. Given that P-TEFb is a global transcriptional
elongation factor important for most pol II transcription (2,
47), it is tempting to propose that, besides its ability to repress
transcription through histone deacetylation, N-CoR/HDAC3
can also repress transcription by suppressing P-TEFb activity
and consequently transcriptional elongation. However, due to
the lack of a specific antibody recognizing acetylated K44 of
CDK9, we have not been able to directly demonstrate that
acetylation on K44 is regulated by N-CoR/HDAC3. Attempts
to generate such antibodies have so far failed. For unknown
reasons, the commercial anti-acetylated K antibodies (Abcam,
Upstate, and Cell Signaling) do not appear to recognize acety-
lated CDK9 (data not shown).
FIG. 7. Evidence that K44R mutation in CDK9 impairs the tran-
scriptional elongation and that tethering components of N-CoR com-
plex to DNA suppresses transcriptional elongation. (A) Schematic
representation of G5-83-HIV-luc reporter and RNase protection assay
for transcriptional elongation. CDK9 kinase activity is required for
overcoming transcriptional pausing at the proximal region. nt, nucle-
otide. (B) HeLa cells were transfected with Gal-CDK9 or Gal-
CDK9(K44R) mutant together with G5-83-HIV-luc reporter. After
overnight incubation, RNase protection assays were performed to de-
tect both the short transcripts resulting from RNA pol II pausing and
long transcripts as a consequence of processive transcriptional elon-
gation. (C) HeLa cells were transfected with Gal-TBL1, Gal-TBLR1,
or Gal-HDAC3, and RNase protection assays were performed as de-
scribed for panel B. (D) A working model illustrates that P-TEFb
transcriptional activity is regulated by dynamic acetylation (Ac) of
CDK9.
VOL. 27, 2007 CDK9 ACETYLATION 4649
 o
n
 June 10, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
As a kinase important for positive transcriptional elonga-
tion, multiple mechanisms have been shown to regulate CDK9
kinase activity. First, the CDK9 kinase activity is dependent on
its association with a cyclin T subunit (42, 43). Second, the
CDK9 kinase activity is regulated by phosphorylation. Like
many other CDKs, phosphorylation on the T-loop by CDK9
itself or another kinase(s) activates CDK9 kinase activity (40).
Third, the CDK9 kinase activity is inhibited by association with
7SK small nuclear RNA and HEXIM1 (37, 41, 56, 57). Previ-
ous studies indicate that about half of cellular P-TEFb is found
to be associated with 7SK and HEXIM1 (38). Interestingly, we
found that almost all CDK9 and HEXIM1 in HeLa nuclear
extract behaved as an 700-kDa complex, and RNase A treat-
ment converted all CDK9 and HEXIM1 to a smaller complex
(Fig. 2D). Since half of P-TEFb was shown to associate with
7SK RNA, this result raises the possibility that P-TEFb may
associate with additional unidentified RNA. Fourth, two re-
cent studies indicated that P-TEFb is positively regulated by
Brd4, a double bromodomain-containing protein (26, 55).
Brd4 was found to associate only with the 7SK/HEXIM1-free
P-TEFb, and this interaction requires the double bromodo-
main of Brd4. The bromodomain is a signature motif for bind-
ing of acetylated lysine (25, 60), and Brd4 has been shown to
bind acetylated histones through double bromodomain (9, 28).
In this study, we found that CDK9 is subjected to acetylation
and deacetylation. We present evidence that acetylation pro-
motes, whereas deacetylation by N-CoR/HDAC3 inhibits, the
P-TEFb transcriptional elongation function. Given Brd4 is a
double bromodomain associated with the active form of P-
TEFb, it is tempting to suggest that, like acetylated histones,
Brd4 may bind preferentially to the acetylated form of CDK9
and maintains its kinase activity in transcriptional elongation
(Fig. 7D). On the contrary, deacetylation of CDK9 by N-CoR/
HDAC3 or other HDACs may reduce the association of CDK9
with Brd4 and thus promotes the interaction of P-TEFb with
7SK and HEXIM1 to form an inactive complex. Thus, acety-
lation of CDK9 could play a regulatory role in partitioning
P-TEFb into an active or inactive complex. In support of this
idea, we show that N-CoR/HDAC3 mainly associates with the
7SK/HEXIM1-containing P-TEFb complex (Fig. 2C). In addi-
tion, TSA treatment dissociates HDAC3 from P-TEFb (Fig.
5D). Alternatively, CDK9 acetylation may affect T-loop phos-
phorylation and thus P-TEFb kinase activity.
In sum, we find in this study that a fraction of the cellular
N-CoR complex is associated with and regulates P-TEFb. Our
study suggests that the P-TEFb activity is likely regulated by
reversible acetylation of CDK9. To our knowledge, our work
identifies CDK9 as the first CDK whose activity is regulated by
acetylation. In addition, our study suggests that, besides its
ability to repress transcription through histone deacetylation,
N-CoR/HDAC3 complex may also repress transcriptional
elongation through its ability to regulate P-TEFb.
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